Talquetamab
(Redirected from Talvey)
Talquetamab is a bispecific antibody used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Talquetamab is designed to target both the GPRC5D protein on myeloma cells and the CD3 receptor on T cells, thereby directing the body's immune system to attack the cancer cells.
Mechanism of Action[edit | edit source]
Talquetamab works by binding to the GPRC5D protein, which is overexpressed on the surface of multiple myeloma cells, and the CD3 receptor on T cells. This dual binding brings the T cells into close proximity with the myeloma cells, facilitating the immune-mediated destruction of the cancer cells. This mechanism is similar to other bispecific antibodies used in cancer therapy, such as blinatumomab.
Clinical Development[edit | edit source]
Talquetamab is currently undergoing clinical trials to evaluate its safety and efficacy in patients with relapsed or refractory multiple myeloma. Early-phase clinical trials have shown promising results, with significant anti-tumor activity observed in patients who have exhausted other treatment options.
Administration and Dosage[edit | edit source]
Talquetamab is administered via intravenous infusion. The dosage and frequency of administration are determined based on the patient's condition, response to treatment, and the specific protocol of the clinical trial or treatment regimen being followed.
Side Effects[edit | edit source]
Common side effects of talquetamab include cytokine release syndrome, neutropenia, anemia, and thrombocytopenia. Patients may also experience fatigue, nausea, and infections. It is important for patients to be monitored closely for these side effects and to receive supportive care as needed.
Related Treatments[edit | edit source]
Other treatments for multiple myeloma include proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies such as daratumumab and elotuzumab. Stem cell transplantation is also a common treatment option for eligible patients.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
-
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
